Filter Results :

Your search for Immune returned 163 reports

Sort by


Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

06 Jan 2017  |  Published by:  MarketsandMarkets
The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.  In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area...

$ 5,650.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). The DelveInsightsReport covers the...

$ 1,250.00

Read More

Primary Immune Deficiency (PID)-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Primary Immune Deficiency (PID)-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Primary Immune Deficiency (PID). The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-...

$ 1,250.00

Read More

Acquired (Autoimmune) Hemolytic Anemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Acquired (Autoimmune) Hemolytic Anemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Acquired (Autoimmune) Hem...

$ 2,000.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective o...

$ 2,000.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura)-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura)-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura). The DelveInsightsReport covers the p...

$ 1,250.00

Read More

Acquired (Autoimmune) Hemolytic Anemia-API Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API ...

$ 1,250.00

Read More

TapImmune Inc (TPIV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

13 Dec 2016  |  Published by:  GlobalData
SummaryTapImmune Inc (TapImmune) is a clinical-stage immuno-oncology company that develops peptide and gene based immunotherapeutics and vaccines in the areas of cancers and infectious diseases. The company's pipeline products include TPIV 200, which is intended for the treatment of ovarian and brea...

$ 250.00

Read More

EpiCast Report: Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2025

01 Dec 2016  |  Published by:  GlobalData
SummaryImmune thrombocytopenia (ITP) is an autoimmune syndrome involving the antibody- and cell-mediated destruction of platelets and the suppression of platelet production; this increases an affected individual's susceptibility to bleeding. More specifically, the destruction and suppression of plat...

$ 3,995.00

Read More

Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

01 Dec 2016  |  Published by:  GBI Research
SummaryCancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while eva...

$ 4,995.00

Read More

Autoimmune Hepatitis Global Clinical Trials Review, H2, 2016

30 Nov 2016  |  Published by:  GlobalData
Summary“Autoimmune Hepatitis Global Clinical Trials Review, H2, 2016" provides an overview of Autoimmune Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Autoimmune Hepatitis. Report includes an overview of trial numbers and their average enro...

$ 2,500.00

Read More

Immunohistochemistry Market by Product (Antibody, Reagent, Kits, Slide Staining System, Tissue Microarray) Application (Diagnostics (Cancer, Cardiovascular, Diabetes, Autoimmune, Infectious Diseases) & Drug Testing) End User - Global Forecast to 2021

29 Nov 2016  |  Published by:  MarketsandMarkets
The immunohistochemistry (IHC) market is projected to reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% during the forecast period of 2016 to 2021. Factors such as the growing prevalence of cancer and rapidly increasing geriatric population across the globe are the primary driving the growth...

$ 5,650.00

Read More

Adimmune Corp (4142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

21 Nov 2016  |  Published by:  GlobalData
SummaryAdimmune Corp (Adimmune) is a pharmaceutical company that manufactures vaccines, diagnostics, and biological products for various diseases. The company offers products such as Japan encephalitis vaccine, tetanus toxoid adsorbed vaccine, influenza vaccine, and ah1n1 vaccine. It also offers ent...

$ 250.00

Read More

Altimmune Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

21 Nov 2016  |  Published by:  GlobalData
SummaryAltimmune Inc (Altimmune), formerly Vaxin Inc, is a clinical stage immunotherapeutic biotechnology company that develops vaccines and other biological products. The company's products include innovative vaccine delivery platforms, immunotherapeutic products, intranasally administered recombin...

$ 250.00

Read More

Altimmune UK Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

21 Nov 2016  |  Published by:  GlobalData
SummaryAltimmune UK Ltd (Altimmune), formerly Vaxin UK Limited, a subsidiary of Altimmune Inc, is a clinical stage immunotherapeutic biotechnology company that develops synthetic vaccines for mutating viruses. The company designs and develops immunotherapeutic products tailored to address a wide ran...

$ 250.00

Read More
Total 163 records.